Oncology Institute (TOIIW) Amortization of Deferred Charges (2021 - 2026)

Oncology Institute (TOIIW) has reported Amortization of Deferred Charges for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $1.2 million, down 75.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (down 50.97% YoY), and the FY2025 annual result was $8.4 million, up 32.91% from the prior year.
• Amortization of Deferred Charges was $1.2 million for Q1 2026 at Oncology Institute, roughly flat from $1.2 million in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $4.9 million in Q1 2025 and troughed at $892000.0 in Q3 2022.
• Average Amortization of Deferred Charges over 5 years is $1.6 million, with a median of $1.6 million recorded in 2022.
• Year-over-year, Amortization of Deferred Charges soared 4855.56% in 2022 and sank 75.15% in 2026.
• Over 5 years, Amortization of Deferred Charges stood at $1.6 million in 2022, then grew by 1.29% to $1.6 million in 2023, then climbed by 1.4% to $1.6 million in 2024, then slipped by 24.4% to $1.2 million in 2025, then gained by 0.5% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.